Ewout Landeloos

Leuven, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype.

Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype.

Journal: Cancer discovery
Published: August 22, 2024

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.

Journal: Oncoimmunology
Published: December 05, 2022

A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma.

A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma.

Journal: Cell
Published: November 10, 2022

Author Correction: A cellular hierarchy in melanoma uncouples growth and metastasis.

Author Correction: A cellular hierarchy in melanoma uncouples growth and metastasis.

Journal: Nature
Published: October 19, 2022

Corrigendum to "itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens".

Corrigendum to "itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens".

Journal: EBioMedicine
Published: June 29, 2021

Epithelial-to-mesenchymal-like transition events in melanoma.

Epithelial-to-mesenchymal-like transition events in melanoma.

Journal: The FEBS journal
Published: March 06, 2021

Correction to: Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.

Correction to: Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.

Journal: Trials
Published: March 06, 2021

Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.

Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.

Journal: Cancer immunology research
Published: January 25, 2021

Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial.

Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial.

Journal: EBioMedicine
Published: November 25, 2020

Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.

Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.

Journal: Trials
Published: August 03, 2020

A cellular hierarchy in melanoma uncouples growth and metastasis.

A cellular hierarchy in melanoma uncouples growth and metastasis.

Journal: Nature
Published: July 01, 2020
Showing 1-11 of 11

Last Updated: 09/26/2026